Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
GSK’s Zejula win is the latest chapter in a long and convoluted history of PARP inhibition.
Lifileucel heads up the list of upcoming US FDA catalysts.
Private company trial initiations stand out in the latest week’s disclosures.
The biotech gives up on the exon 20 market, and says Tagrisso’s initial setting is no longer meaningful in the west.
A just revealed phase 3 trial will apparently pit a fixed-dose combo head to head against Opdualag.
For now, the group is sticking with what it knows ahead of a big year in lymphoma.